tecovirimat

Phase 3

SIGA TECHNOLOGIES INC (SIGA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Smallpox

View Full Landscape

Drug Information

Target Indication

Smallpox

Clinical Trial

NCT02474589

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/6/2022

Tecovirimat SIGA

Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13kg: Smallpox Cowpox Tecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13kg . Tecovirimat SIGA should be used in accordance with official recommendations.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SIGA

SIGA TECHNOLOGIES INC

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

TPOXXPhase 3

Smallpox

Smallpox and Mpox VaccinePhase 2

Smallpox

ST-246 400 mgPhase 2

Orthopoxviral Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts